Literature DB >> 8381255

Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns.

M Forsting1, F K Albert, S Kunze, H P Adams, D Zenner, K Sartor.   

Abstract

PURPOSE: To optimize the timing of CT and MR after glioblastoma resection and to define the pattern of tumor regrowth. SUBJECTS AND METHODS: Sixty-eight patients with glioblastoma were studied prospectively with CT and MR. The first postoperative scan was obtained between day 1 and day 5; follow-up scans were obtained bimonthly.
RESULTS: Residual tumor was shown most reliably on scans obtained shortly after surgery (MR, 77%; CT, 40.5%). After the fourth day up to 3 months postoperatively, surgically induced enhancement prevented recognition of residual tumor. Seventy-five percent of patients with residual tumor shown by early postoperative MR had progressive disease during follow-up, whereas only 36% of patients without evidence of residual tumor had MR signs of progressive disease.
CONCLUSION: Early, enhanced, postoperative MR is the radiologic procedure of choice to determine the extent of glioblastoma resection. Gross total tumor resection as determined by early postoperative MR correlates with a prolongation of life.

Entities:  

Mesh:

Year:  1993        PMID: 8381255      PMCID: PMC8334428     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  16 in total

1.  Surgically induced intracranial contrast enhancement: potential source of diagnostic error in intraoperative MR imaging.

Authors:  M Knauth; N Aras; C R Wirtz; A Dörfler; T Engelhorn; K Sartor
Journal:  AJNR Am J Neuroradiol       Date:  1999-09       Impact factor: 3.825

2.  Estimation of tumor volume with fuzzy-connectedness segmentation of MR images.

Authors:  Gul Moonis; Jianguo Liu; Jayaram K Udupa; David B Hackney
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

3.  Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Authors:  Andrea Pirzkall; Colleen McGue; Suja Saraswathy; Soonmee Cha; Raymond Liu; Scott Vandenberg; Kathleen R Lamborn; Mitchel S Berger; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

4.  Correlation of intra-operative ultrasound with histopathologic findings after tumour resection in supratentorial gliomas. A method to improve gross total tumour resection.

Authors:  M Woydt; A Krone; G Becker; K Schmidt; W Roggendorf; K Roosen
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  Spontaneous regression of residual low-grade cerebellar pilocytic astrocytomas in children.

Authors:  Roxana S Gunny; Richard D Hayward; Kim P Phipps; Brian N Harding; Dawn E Saunders
Journal:  Pediatr Radiol       Date:  2005-07-27

6.  How treatment monitoring is influencing treatment decisions in glioblastomas.

Authors:  Martha R Neagu; Raymond Y Huang; David A Reardon; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

7.  Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.

Authors:  Jun-Ling Xu; Yong-Li Li; Jian-Min Lian; She-wei Dou; Feng-Shan Yan; Hui Wu; Da-peng Shi
Journal:  Neuroradiology       Date:  2010-06-23       Impact factor: 2.804

8.  Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.

Authors:  Fabian Baumann; Miroslava Bjeljac; Spyros S Kollias; Brigitta G Baumert; Sebastian Brandner; Valentin Rousson; Yasuhiro Yonekawa; René L Bernays
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 9.  Neuroradiologic review in pediatric brain tumor studies.

Authors:  Monika Warmuth-Metz; Brigitte Bison; Susanne Leykamm
Journal:  Klin Neuroradiol       Date:  2009-11-21

10.  Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

Authors:  C Goetz; P Riva; G Poepperl; F J Gildehaus; A Hischa; K Tatsch; H J Reulen
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.